Oasmia Pharmaceutical (VIVE)
Free
No email, no account, no signup.
Pulling latest news for Oasmia Pharmaceutical…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
3/10
Risk
8/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment remains negative, centered on dilution, micro-cap risk and the reverse split, but is slightly more wait-and-see after financing/capital actions and study execution were confirmed.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Oncology drug development (human and veterinary)
Market Cap
$8M
Market sentiment
Sentiment remains negative, centered on dilution, micro-cap risk and the reverse split, but is slightly more wait-and-see after financing/capital actions and study execution were confirmed.
Why NEUTRAL ?
The previously 'imminent report/AGM' catalyst has now passed, but the reverse split decision and issuance mandate increase the likelihood of further capital actions. With zero revenues and Cantrixil still in early-stage work, binary execution risk remains high; the next clearer datapoints are continued study progress and the H1/Q2 report.
- Hold/wait with a small watch position; avoid adding until clearer study data or improved funding visibility after the split is implemented and any potential new issuance is clarified.
Recent News
- Since the last analysis, Vivesto has executed a 1:100 reverse share split (post-split trading from 20 May 2026) and subsequently announced the new number of shares and votes (11,071,369 shares). No new interim reports, financing announcements, or clinical data points are reflected in the provided material beyond this; the next scheduled report is Q2 on 13 August 2026.
Bull case
- **May 2026 report/AGM** may clarify cash position and strategy
- **Reverse split** could reduce “penny stock” stigma and improve trading
- **Study progress** headlines can drive short-term upside volatility
Unlock to read more →
Bear case
- **Reverse splits** are often perceived negatively in microcap biotech
- Continued **near-zero revenue** and losses may pressure the share price
- Low liquidity and weak sentiment can amplify drawdowns
Unlock to read more →
Catalysts
15 Aug 2026 — Cantrixil: PK/tox update
Dilution Risk
Assessment: High
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Oasmia Pharmaceutical – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.